INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2001

Oral curcumin up to 8,000 mg/day for 3 months was non-toxic and showed potential histologic improvement in some precancerous lesions.

A phase I trial evaluated oral curcumin taken for 3 months in 25 patients across five high-risk conditions, escalating doses up to 12,000 mg/day. No treatment-related toxicity occurred up to 8,000 mg/day (doses beyond this were unacceptable due to bulky volume), with average peak serum concentrations reaching 1.77 +/- 1.87 microM at 8,000 mg. Histologic improvement was observed in 1 of 2 resected bladder cancer patients, 2 of 7 oral leucoplakia patients, 1 of 6 intestinal metaplasia patients, 1 of 4 CIN patients, and 2 of 6 Bowen's disease patients, although frank malignancies developed in 1 CIN and 1 oral leucoplakia patient.

Study type
Phase I dose-escalation clinical trial
Who was studied
25 patients with high-risk or pre-malignant lesions
What was measured
Toxicity, pharmacokinetics, and histologic changes in precancerous lesions

THE PAPER

Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.

Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. Anticancer Res, 2001.

PubMed 11712783 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.